Fig. 2
Melanocyte cell-fate gene expression characterizes vemurafenib relapse in murine and human tumors. a, b Normalized RNA-seq RPKM values plotted for matched biopsies for mature melanocyte markers (a, n = 17) or neural crest-like markers (b, n = 17). c Differentiation change from baseline score of melanoma differentiation genes (BACE2, EDNRB, GPNMB, KIT, MITF, MLANA, PMEL, TYRP1, ZEB2) derived from ref. [6] in matched pre-treatment and progressed biopsies from melanoma patient samples (n = 23 pairs) from BRIM clinical trials [41] and d from melanoma patient samples (n = 31 pairs) from ref. [21]. Bars outlined in red are patients whose tumors acquired a MAPK pathway mutation at time of vemurafenib progression. Data are plotted as direct RPKM values in a, b. p-values determined by t-test in a, b. IB: initial biopsy; VPr: vemurafenib-progressed samples
